A new platelet parameter, the mean platelet component, can demonstrate abnormal platelet function and structure in

D R Brummitt1, H F Barker, N Pujol-Moix

  • 1Department of Haematology, Rotherham General Hospitals NHS Trust, Rotherham, S60 2UD, UK.

Insights

Low mean platelet component (MPC) levels may indicate platelet dysfunction in myelodysplasia patients. This inexpensive test can help screen for ultrastructural abnormalities, aiding in diagnosing bleeding complications.

Area of Science:

  • Hematology
  • Clinical Pathology

Background:

  • The mean platelet component (MPC) is a novel parameter from the Bayer ADVIA 120 analyser.
  • Complete blood count (CBC) analysis routinely includes MPC.
  • Myelodysplasia can present with bleeding issues and abnormal bleeding times.

Observation:

  • A case study involving myelodysplasia with bleeding complications and abnormal bleeding time was analyzed.
  • Low MPC parameters were observed in the patient.
  • Transmission electron microscopy revealed partial platelet granule deficiency.

Findings:

  • Low MPC values correlated with partial platelet granule deficiency in the myelodysplasia case.
  • This suggests a link between MPC and platelet ultrastructure.

Implications:

  • Mean platelet component (MPC) may serve as a cost-effective and rapid screening tool for platelet dysfunction.
  • It can identify patients with myelodysplasia and potential ultrastructural platelet abnormalities.
  • This aids in managing bleeding complications associated with myelodysplasia.